Neurofit Obtains Japanese Medical Device Certification for Degenerative Brain Disease Guide Solution 'Neurofit Aqua'

[Asia Economy Reporter Jang Hyowon] Neurofit, a specialized company in AI solutions for brain disease imaging, has become the first to obtain Japanese certification for its main brain imaging analysis product and is launching its entry into the Japanese market, the largest medical device market in Asia.

Neurofit announced on the 6th that it has obtained medical device certification from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its degenerative brain disease diagnostic guide software, "Neurofit AQUA (NEUROPHET AQUA)."

Neurofit AQUA is a brain imaging analysis medical device software that analyzes brain MRI (magnetic resonance imaging) using AI technology to assess brain atrophy and white matter degeneration observed in neurodegenerative diseases such as Alzheimer's disease and vascular dementia.

The existing brain imaging analysis product, which is based on atlas software, requires about 8 to 24 hours just for brain image segmentation and has a high failure rate in analysis, making it difficult for medical professionals to use. In particular, it can only analyze based on Western brain standards, limiting its ability to analyze the brains of Koreans and Asians.

Neurofit AQUA uses a self-developed AI engine to enable brain image segmentation and analysis in just 5 minutes, boasting a 0% failure rate and a high success rate in analysis. It can analyze brain images regardless of race, age, or gender, and supports image analysis from various MRI devices from global manufacturers such as GE, Philips, and Canon.

Neurofit AQUA, which has obtained Japanese certification, is the AQUA Premium product capable of quantifying brain atrophy analysis for dementia diagnosis and the severity of white matter degeneration frequently found in patients with vascular dementia and stroke.

With this certification, Neurofit AQUA can now be officially sold in Japan, and Neurofit plans to collaborate with major local medical device distribution companies to actively market Neurofit AQUA.

Bin Jungil, CEO of Neurofit, said, "Alzheimer's disease, a representative neurodegenerative disease, is differentiated by medical professionals interpreting brain MRIs when cognitive function problems occur. The global standard for differentiating Alzheimer's disease is analyzing brain MRIs, and with the increase in Alzheimer's patients, we expect Neurofit AQUA to be widely used in the global market."

He added, "We are currently engaged in multifaceted discussions with major Japanese medical device distributors for local sales of Neurofit AQUA, and it is expected that Neurofit AQUA will soon be used in Japanese hospitals and screening centers."